1-amino-4-(4-pyridinyl)oxynaphthalene | 340825-38-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-amino-4-(4-pyridinyl)oxynaphthalene
• 英文别名: 4-pyridin-4-yloxynaphthalen-1-amine
• CAS: 340825-38-9
• 化学式: C₁₅H₁₂N₂O
• mdl: MFCD19516790
• 分子量: 236.273
• InChiKey: WKDHSPAMWBZKDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-amino-4-(4-pyridinyl)oxynaphthalene 、 1-(4-氟苯基)-2-氧代-1,2-二氢吡啶-3-羧酸 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(4-fluorophenyl)-2-oxo-N-(4-pyridin-4-yloxynaphthalen-1-yl)pyridine-3-carboxamide
  参考文献：
  名称：

  Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage

  摘要：

  Necroptosis has been implicated in a variety of disease states, and RIPK3 is one of the kinases identified to play a critical role in this signaling pathway. In an effort to identify RIPK3 kinase inhibitors with a novel profile, mechanistic studies were incorporated at the hit triage stage. Utilization of these assays enabled identification of a Type II DFG-out inhibitor for RIPK3, which was confirmed by protein crystallography. Structure-based drug design on the inhibitors targeting this previously unreported conformation enabled an enhancement in selectivity against key off-target kinases.

  DOI：

  10.1021/acsmedchemlett.9b00065
• 作为产物：
  描述：

  4-硝基-1-萘酚 在 tin(II) chloride dihdyrate 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 乙酸乙酯 为溶剂， 反应 7.5h， 生成 1-amino-4-(4-pyridinyl)oxynaphthalene
  参考文献：
  名称：

  Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage

  摘要：

  Necroptosis has been implicated in a variety of disease states, and RIPK3 is one of the kinases identified to play a critical role in this signaling pathway. In an effort to identify RIPK3 kinase inhibitors with a novel profile, mechanistic studies were incorporated at the hit triage stage. Utilization of these assays enabled identification of a Type II DFG-out inhibitor for RIPK3, which was confirmed by protein crystallography. Structure-based drug design on the inhibitors targeting this previously unreported conformation enabled an enhancement in selectivity against key off-target kinases.

  DOI：

  10.1021/acsmedchemlett.9b00065

文献信息

• 1,4-Disubstituted benzo-fused compounds
  申请人：——

  公开号：US20030083333A1

  公开（公告）日：2003-05-01

  Disclosed are novel 1,4-disubstituted benzo-fused compounds wherein G, X, L, Q, n and Y are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds. 1

  揭示了一种新型的1,4-二取代苯并化合物，其中G、X、L、Q、n和Y在此定义。这些化合物在制备用于治疗涉及炎症的疾病或病理状况的药物组合物中很有用，如慢性炎症性疾病。还公开了制备这些化合物的方法。
• Compounds useful as anti-inflammatory agents
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US06492393B1

  公开（公告）日：2002-12-10

  Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

  揭示了一种新颖的芳香化合物，其化学式为（I），其中G、X、Ar、L和Q在此处有定义。这些化合物在制备用于治疗涉及炎症的疾病或病理状况的药物组合物中具有用途，如慢性炎症性疾病。还揭示了制备这些化合物的方法。
• Compounds use as anti-inflammatory agents
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030125354A1

  公开（公告）日：2003-07-03

  Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds. 1

  本发明揭示了一种式(I)的新型芳香化合物，其中G、X、Ar、L和Q在此处定义。这些化合物可用于制备药物组合物，用于治疗涉及炎症的疾病或病理情况，如慢性炎症性疾病。本发明还揭示了制备这种化合物的方法。
• UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
  申请人：BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

  公开号：EP1232150A1

  公开（公告）日：2002-08-21
• 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS
  申请人：BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

  公开号：EP1381592A1

  公开（公告）日：2004-01-21